RxDoctor Payments Data

Anthony Ragusa, MD

Internal Medicine · Rochester, NYNPI 1962470229

Payments from drug & device makers

$5,143in general payments, 2019–2025

Across 123 payments — averaging $41.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$3K
  • Novo Nordisk$685
  • Amarin Pharma, Inc.$358
  • Esperion Therapeutics, Inc.$170
  • Lilly USA, LLC$161
  • Johnson & Johnson$130
  • plus $371 from 7 others

What the payments were for

  • Food & beverage$5,143100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,143 in reported general payments places this provider in the 85th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$18,356
Medicare patients
23
Services billed
141

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide67$116,879
EliquisApixaban69$100,369
JardianceEmpagliflozin34$41,108
OxycontinOxycodone Hcl25$37,301
EntrestoSacubitril/Valsartan24$26,353
TrulicityDulaglutide18$21,187
InvokanaCanagliflozin13$18,235
Icosapent Ethyl48$16,497
FarxigaDapagliflozin Propanediol20$16,136
XareltoRivaroxaban11$15,100
Rosuvastatin Calcium283$7,838
Breztri AerosphereBudesonide/Glycopyr/Formoterol12$7,279
Ezetimibe108$6,254
Lantus SolostarInsulin Glargine,hum.Rec.Anlog18$3,830
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen97$3,268

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$685$116,87967 claims
PfizerEliquis, Paxlovid$120$103,07681 claims
Boehringer IngelheimJardiance$17$41,10834 claims
Johnson & JohnsonInvokana, Xarelto$130$33,33624 claims
NovartisEntresto$21$26,35324 claims
Lilly USA, LLCTrulicity$161$21,18718 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Rochester

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →